Open an account

Simulations Plus

SLP · NASDAQ

$18.50+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About SLP

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The company is headquartered in Research Triangle Park, North Carolina and currently employs 212 full-time employees. The firm helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The firm's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.

Employees
212
Headquarters
RESEARCH TRIANGLE PARK, North Carolina
Listed
Jun 18, 1997
Sector
Health Care
Industry
Health Care Technology
Website
simulations-plus.com

SLP key statistics

Market cap
374.16M
Price-earnings ratio
46.25
Dividend yield
—
Average volume
265.80K
Volume
625.33K
Open price
$18.50
High today
$18.50
Low today
$18.49
52 Week high
$21.01
52 Week low
$11.09

Simulations Plus (SLP) at a glance

Simulations Plus (SLP) last traded at $18.50, with a market cap of 374.16M and a price-to-earnings ratio of 46.25.

Today the stock has traded between $18.49 and $18.50. The current price is 0.1% above the day's low and 0.0% below its high.

Volume so far is 625.33K shares, above the average of 265.80K shares a day.

Over the past year Simulations Plus has ranged from $11.09 to $21.01, and now sits 75% of the way up that range.

Simulations Plus met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q3 FY26 it reported $0.18 per share against an estimate of $0.1279.

The average analyst price target is $17.59, 4.9% below the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 3 analyst ratings say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 3 analystsAvg $17.59
Low
$16.16
Now
$18.50
High
$19.42

SLP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 75.7% on average.

  1. Q4 FY24: reported $0.04 per share against an estimate of $0.0444
  2. Q1 FY25: reported $0.01 per share against an estimate of $0.1071
  3. Q2 FY25: reported $0.15 per share against an estimate of $0.149
  4. Q3 FY25: reported $0.45 per share against an estimate of $0.1069
  5. Q4 FY25: reported -$0.03 per share against an estimate of -$0.0505
  6. Q1 FY26: reported $0.22 per share against an estimate of $0.1995
  7. Q2 FY26: reported $0.18 per share against an estimate of $0.1279
  8. Q3 FY26: reported $0.18 per share against an estimate of $0.1279

SLP news

  • Press releaseBusiness Wire

    Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

  • Press releaseBusiness Wire

    Simulations Plus Announces Completion of Acquisition by Altaris

  • Press releaseBusiness Wire

    Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

  • Press releaseBusiness Wire

    Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris

  • Press releasePRNewswire

    Are DSGR, AVB, SLP, APGE Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP

  • Press releasePRNewswire

    SLP Shareholder Alert: Robbins LLP is Investigating Allegations that the Officers and Directors of Simulation Plus, Inc., Violated Securities Laws and Breached Fiduciary Duties to Shareholders

  • Press releaseBusiness Wire

    Simulation Plus, Inc. (NASDAQ: SLP) Investors Should Contact Robbins LLP for Information About Investigation

Similar companies

Companies in the same industry as Simulations Plus

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.